Symphogen is the leader in developing recombinant antibody mixtures (known as rpAbs), a new class of biopharmaceuticals for the treatment or prophylaxis of serious human diseases. Symphogen is developing rpAb product candidates for therapeutic areas where there is the highest potential to provide improved prophylactic or therapeutic options over current drugs. rpAb therapies may confer greater efficacy, safety and convenience due to their ability to capture the features of the natural human immune response, making them a potentially more attractive treatment option.
Recombinant antibody mixtures hold promise for a range of therapeutic applications. Symphogen is focusing its drug discovery and development efforts on the replacement of plasma-derived immunoglobulins, prevention or treatment of infectious disease, and treatment of cancer.
